Health News (Reuters)

New cancer drugs help Johnson & Johnson top profit estimates

(Reuters) - Johnson & Johnson posted better-than-expected third-quarter earnings, raising its full-year forecast due to growth from new cancer drugs and high-margin treatments picked up in its $30 billion acquisition of Actelion earlier this year.

Florida needs more pet-friendly hurricane shelters for the elderly

(Reuters Health) - When pet owners need to flee from disasters like hurricanes and fires, they often think first of their animals, but a new study suggests a scarcity of pet-friendly emergency shelters could make older evacuees all the more vulnerable.

UnitedHealth sees growth in 2018, opportunities in Trump plans

(Reuters) - UnitedHealth Group Inc, the largest U.S. health insurer, said earnings will grow 13 to 16 percent in 2018 as medical costs remain low, and that it expects to benefit from new insurance products backed by U.S. President Donald Trump.

Trump's drug czar nominee withdraws from consideration

WASHINGTON (Reuters) - President Donald Trump's pick for U.S. drug czar withdrew on Tuesday after it become public that he spearheaded a bill that undercut the government's power to crack down on opioid makers that were flooding the market with the addictive painkillers.

Drugmakers Amneal, Impax to combine in generics push

(Reuters) - Amneal Pharmaceuticals LLC is buying peer Impax Laboratories Inc in an all-stock deal as it looks to add heft to its generics business and gain an edge in a tough drug pricing environment.

New cancer drugs help J&J top profit estimates

(Reuters) - Johnson & Johnson reported a higher-than-expected quarterly profit and raised its full-year forecast as the company gained from strong sales of its new cancer drugs.

Chi-Med, AstraZeneca lung cancer drug shrinks resistant tumors

LONDON (Reuters) - An experimental cancer drug discovered by Hutchison China MediTech has demonstrated promising activity in shrinking tumors in lung cancer patients whose disease had worsened following treatment with approved medicines.

Trump says he could jettison drug czar pick

WASHINGTON (Reuters) - U.S. President Donald Trump said on Monday he would review a report that his nominee for drug czar championed a law that weakened the government's ability to fight the nation's opioid epidemic, and said he could consider jettisoning the pick.

Regeneron-Sanofi drug succeeds mid-stage study

(Reuters) - Regeneron Pharmaceuticals Inc and Sanofi SA said on Monday their drug to treat inflammation in the esophagus, mainly caused by food allergies, met the main goal of a mid-stage study.

U.S. judge in Texas invalidates Allergan patents on Restasis

(Reuters) - A U.S. judge on Monday invalidated patents on Allergan Plc's dry-eye medicine Restasis on grounds that the patents cover ideas that are obvious, sending shares of the pharmaceutical company down 3.5 percent.

Trump says he will 'look into' drug czar pick following report

WASHINGTON (Reuters) - U.S. President Donald Trump said on Monday that he would "look into" a report that his nomination for drug czar championed a law weakening the Drug Enforcement Administration's capacity to slow the flow of drugs that have fueled the country's opioid epidemic.

Pages